Wenchang Yue: Why Recurrence and Progression in Bladder Cancer Require Different Approaches - Oncodaily
Wenchang Yue: Why Recurrence and Progression in Bladder Cancer Require Different Approaches Oncodaily
Bladder Cancer News
DHCR24+ tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling | Oncogene - Nature
DHCR24+ tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling | Oncogene Nature
Bladder cancer detected up to five years before diagnosis—thanks to AI - Medical Xpress
Bladder cancer detected up to five years before diagnosis—thanks to AI Medical Xpress
Enfortumab Vedotin Plus Pembrolizumab Beats Chemo in Muscle Invasive Bladder Cancer - Oncology News Central
Enfortumab Vedotin Plus Pembrolizumab Beats Chemo in Muscle Invasive Bladder Cancer Oncology News Central
3 reasons why an accurate bladder cancer diagnosis matters - UT MD Anderson
3 reasons why an accurate bladder cancer diagnosis matters UT MD Anderson
Beloved rock frontman dead at 69 after bladder cancer battle: ‘Boston music legend’ - PennLive.com
Beloved rock frontman dead at 69 after bladder cancer battle: ‘Boston music legend’ PennLive.com
Urine Tumour DNA Predicts Bladder Cancer Recurrence - EMJ
Urine Tumour DNA Predicts Bladder Cancer Recurrence EMJ
Defining High-Risk NMIBC and Diagnostic Gaps Before Referral - Urology Times
Defining High-Risk NMIBC and Diagnostic Gaps Before Referral Urology Times
KRAS G12C mutation identified as a rare potential target in genitourinary cancers - EurekAlert!
KRAS G12C mutation identified as a rare potential target in genitourinary cancers EurekAlert!
New Combination Therapy Shows Promise for Advanced Bladder Cancer - University of Colorado Anschutz
New Combination Therapy Shows Promise for Advanced Bladder Cancer University of Colorado Anschutz
Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer - The ASCO Post
Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer The ASCO Post
Bladder Cancer Therapy Enfortumab Vedotin (Padcev®) Provides Lasting Benefits, Long-Term Data Confirms - Memorial Sloan Kettering Cancer Center
Bladder Cancer Therapy Enfortumab Vedotin (Padcev®) Provides Lasting Benefits, Long-Term Data Confirms Memorial Sloan Kettering Cancer Center
Bladder Cancer Care Is Entering a New Era - Medscape
Bladder Cancer Care Is Entering a New Era Medscape
Experimental immunotherapy may help patients with high-risk bladder cancer avoid bladder removal surgery - Mayo Clinic News Network
Experimental immunotherapy may help patients with high-risk bladder cancer avoid bladder removal surgery Mayo Clinic News Network
Enrique Grande: IBCG Brings Global Experts Together to Care for Bladder Cancer Patients - Oncodaily
Enrique Grande: IBCG Brings Global Experts Together to Care for Bladder Cancer Patients Oncodaily
FDA Approves Perioperative Pembro Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer - Oncology News Central
FDA Approves Perioperative Pembro Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer Oncology News Central
Stephen Williams: IBCG26 Advances the Discussion on Value in Bladder Cancer Care - Oncodaily
Stephen Williams: IBCG26 Advances the Discussion on Value in Bladder Cancer Care Oncodaily
Key Bladder Cancer Trials to Watch in 2026 - Oncology News Central
Key Bladder Cancer Trials to Watch in 2026 Oncology News Central
Shilpa Gupta: Global Patient Voices Unite for Better Bladder Cancer Care - Oncodaily
Shilpa Gupta: Global Patient Voices Unite for Better Bladder Cancer Care Oncodaily
Petros Grivas: Stellar Colleagues and Patient Inspiration Drive IBCG Meeting - Oncodaily
Petros Grivas: Stellar Colleagues and Patient Inspiration Drive IBCG Meeting Oncodaily
A new sensor could enable earlier detection of bladder cancer - MIT News
A new sensor could enable earlier detection of bladder cancer MIT News
Spatial map of bladder cancer reveals hidden tumor environments and new paths toward precision therapy - UT MD Anderson
Spatial map of bladder cancer reveals hidden tumor environments and new paths toward precision therapy UT MD Anderson
Beyond the diagnosis: What living with bladder cancer really looks like - Johnson & Johnson
Beyond the diagnosis: What living with bladder cancer really looks like Johnson & Johnson
Bladder Cancer: What You Need to Know to Detect It Early - Dana-Farber Cancer Institute
Bladder Cancer: What You Need to Know to Detect It Early Dana-Farber Cancer Institute
Immune Biomarkers May Predict Response to Bladder Cancer Treatment - Northwestern University
Immune Biomarkers May Predict Response to Bladder Cancer Treatment Northwestern University
New study looks at pesticide exposure and bladder cancer risk among Hmong farmworkers - UC Davis Health
New study looks at pesticide exposure and bladder cancer risk among Hmong farmworkers UC Davis Health
Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer. - AstraZeneca
Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer. AstraZeneca
A Urine Test That Could Change the Course of Bladder Cancer Care - Stanford Medicine
A Urine Test That Could Change the Course of Bladder Cancer Care Stanford Medicine
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer - The New England Journal of Medicine
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer The New England Journal of Medicine
Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms - ASCO Publications
Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms ASCO Publications
Bladder Cancer Treatment Is Changing: What Patients Should Know - Cure Today
Bladder Cancer Treatment Is Changing: What Patients Should Know Cure Today
ASCO 2026: Discussant – Curing Early Bladder Cancer with Multidisciplinary Approaches - UroToday
ASCO 2026: Discussant – Curing Early Bladder Cancer with Multidisciplinary Approaches UroToday
WVU Cancer Institute expands bladder cancer treatment options for patients across region - WVU Medicine
WVU Cancer Institute expands bladder cancer treatment options for patients across region WVU Medicine
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery - Fox Chase Cancer Center
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery Fox Chase Cancer Center
Urinary microbiota in bladder cancer: insights into pathogenesis, diagnosis, and therapeutic potential - Frontiers
Urinary microbiota in bladder cancer: insights into pathogenesis, diagnosis, and therapeutic potential Frontiers
Ep. 4 | Over a Decade Cancer-Free from Bladder Cancer, Driven by NK Cells, T-Cells and Immune Memory - Los Angeles Times
Ep. 4 | Over a Decade Cancer-Free from Bladder Cancer, Driven by NK Cells, T-Cells and Immune Memory Los Angeles Times
Ferroptosis as a therapeutic vulnerability in ARID1A -deficient bladder cancer - Nature
Ferroptosis as a therapeutic vulnerability in ARID1A -deficient bladder cancer Nature
Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial - AstraZeneca
Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial AstraZeneca
Immunotherapy Shows Early Promise in Sparing Cancer Patients From Bladder Removal - NYU Langone Health
Immunotherapy Shows Early Promise in Sparing Cancer Patients From Bladder Removal NYU Langone Health
NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing - CancerNetwork
NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing CancerNetwork